In this meta-analysis of 15 studies of daratumumab- or isatuximab-based first-line regimens in newly diagnosed multiple myeloma, which findings were reported?
Overall response rate was slightly higher with daratumumab (94% vs 91%), PFS was similar, and grade ≥3 infections were less frequent with isatuximab
PFS was significantly longer with isatuximab, but grade ≥3 infections were more frequent with isatuximab
Overall response rate was significantly higher with isatuximab, and PFS was significantly longer with daratumumab